T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies - Marasco, Vincenzo; Carniti, Cristiana; Guidetti, Anna; Farina, Lucia; Magni, Martina; Miceli, Rosalba; Calabretta, Ludovica; Verderio, Paolo; Ljevar, Silva; Serpenti, Fabio; Morelli, Daniele; Apolone, Giovanni; et al. (British journal of haematology, 2022)
Keywords: 2019-nCoV Vaccine mRNA-1273 - administration & dosage; 2019-nCoV Vaccine mRNA-1273 - immunology; Aged; Antibodies, Viral - immunology; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; anti‐CD20 antibody; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - immunology; CD20 antigen; Chemotherapy; Chronic lymphocytic leukemia; COVID-19; COVID-19 - immunology; COVID-19 - prevention & control; Female; Hematologic Neoplasms - drug therapy; Hematologic Neoplasms - immunology; Hematology; Humans; Immune response; Immune response (cell-mediated); Immunity, Cellular - drug effects; Immunoglobulin M; Immunoglobulin M - immunology; lymphoid malignancies; Lymphoma; Lymphoproliferative Disorders - drug therapy; Lymphoproliferative Disorders - immunology; Male; Middle Aged; mRNA; Multiple myeloma; Multivariate analysis; Patients; Prospective Studies; Research Paper; SARS-CoV-2 - immunology; Seroconversion; Serology; Severe acute respiratory syndrome coronavirus 2; T-Lymphocytes - immunology; T‐cell immune response; COVID-19; Seroconversion; anti-CD20 antibody; lymphoid malignancies; T-cell immune response